Improved resistance to ischemia and reperfusion, but impaired protection by ischemic preconditioning in patients with type 1 diabetes mellitus: a pilot study. 2012

Richard Engbersen, and Niels P Riksen, and Marc J Mol, and Bert Bravenboer, and Otto C Boerman, and Patrick Meijer, and Wim J G Oyen, and Cees Tack, and Gerard A Rongen, and Paul Smits
Department of Pharmacology-Toxicology, Radboud University Nijmegen Medical Centre, P,O, Box 9101, Nijmegen, 6500 HB, The Netherlands.

BACKGROUND In patients with type 1 diabetes mellitus (T1DM), cardiovascular events are more common, and the outcome following a myocardial infarction is worse than in nondiabetic subjects. Ischemic or pharmacological preconditioning are powerful interventions to reduce ischemia reperfusion (IR)-injury. However, animal studies have shown that the presence of T1DM can limit these protective effects. Therefore, we aimed to study the protective effect of ischemic preconditioning in patients with T1DM, and to explore the role of plasma insulin and glucose on this effect. METHODS 99mTechnetium-annexin A5 scintigraphy was used to detect IR-injury. IR-injury was induced by unilateral forearm ischemic exercise. At reperfusion, Tc-annexin A5 was administered, and IR-injury was expressed as the percentage difference in radioactivity in the thenar muscle between the experimental and control arm 4 hours after reperfusion. 15 patients with T1DM were compared to 21 nondiabetic controls. The patients were studied twice, with or without ischemic preconditioning (10 minutes of forearm ischemia and reperfusion). Patients were studied in either normoglycemic hyperinsulinemic conditions (n=8) or during hyperglycemic normoinsulinemia (n=7). The controls were studied once either with (n=8) or without (n=13) ischemic preconditioning. RESULTS Patients with diabetes were less vulnerable to IR-injury than nondiabetic healthy controls (12.8 ± 2.4 and 11.0 ± 5.1% versus 27.5 ± 4.5% in controls; p<0.05). The efficacy of ischemic preconditioning to reduce IR-injury, however, was lower in the patients and was even completely abolished during hyperglycemia. CONCLUSIONS Patients with T1DM are more tolerant to forearm IR than healthy controls in our experimental model. The efficacy of ischemic preconditioning to limit IR-injury, however, is reduced by acute hyperglycemia. BACKGROUND The study is registered at www.clinicaltrials.gov (NCT00184821).

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D012039 Regional Blood Flow The flow of BLOOD through or around an organ or region of the body. Blood Flow, Regional,Blood Flows, Regional,Flow, Regional Blood,Flows, Regional Blood,Regional Blood Flows
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D005542 Forearm Part of the upper extremity in humans and primates extending from the ELBOW to the WRIST. Antebrachium,Antebrachiums,Forearms
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006946 Hyperinsulinism A syndrome with excessively high INSULIN levels in the BLOOD. It may cause HYPOGLYCEMIA. Etiology of hyperinsulinism varies, including hypersecretion of a beta cell tumor (INSULINOMA); autoantibodies against insulin (INSULIN ANTIBODIES); defective insulin receptor (INSULIN RESISTANCE); or overuse of exogenous insulin or HYPOGLYCEMIC AGENTS. Compensatory Hyperinsulinemia,Endogenous Hyperinsulinism,Exogenous Hyperinsulinism,Hyperinsulinemia,Hyperinsulinemia, Compensatory,Hyperinsulinism, Endogenous,Hyperinsulinism, Exogenous

Related Publications

Richard Engbersen, and Niels P Riksen, and Marc J Mol, and Bert Bravenboer, and Otto C Boerman, and Patrick Meijer, and Wim J G Oyen, and Cees Tack, and Gerard A Rongen, and Paul Smits
September 2010, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Richard Engbersen, and Niels P Riksen, and Marc J Mol, and Bert Bravenboer, and Otto C Boerman, and Patrick Meijer, and Wim J G Oyen, and Cees Tack, and Gerard A Rongen, and Paul Smits
March 2019, IUBMB life,
Richard Engbersen, and Niels P Riksen, and Marc J Mol, and Bert Bravenboer, and Otto C Boerman, and Patrick Meijer, and Wim J G Oyen, and Cees Tack, and Gerard A Rongen, and Paul Smits
January 2017, EXCLI journal,
Richard Engbersen, and Niels P Riksen, and Marc J Mol, and Bert Bravenboer, and Otto C Boerman, and Patrick Meijer, and Wim J G Oyen, and Cees Tack, and Gerard A Rongen, and Paul Smits
July 2004, Brain research,
Richard Engbersen, and Niels P Riksen, and Marc J Mol, and Bert Bravenboer, and Otto C Boerman, and Patrick Meijer, and Wim J G Oyen, and Cees Tack, and Gerard A Rongen, and Paul Smits
June 2007, Neuroscience and behavioral physiology,
Richard Engbersen, and Niels P Riksen, and Marc J Mol, and Bert Bravenboer, and Otto C Boerman, and Patrick Meijer, and Wim J G Oyen, and Cees Tack, and Gerard A Rongen, and Paul Smits
February 2016, Journal of molecular and cellular cardiology,
Richard Engbersen, and Niels P Riksen, and Marc J Mol, and Bert Bravenboer, and Otto C Boerman, and Patrick Meijer, and Wim J G Oyen, and Cees Tack, and Gerard A Rongen, and Paul Smits
January 2017, American journal of translational research,
Richard Engbersen, and Niels P Riksen, and Marc J Mol, and Bert Bravenboer, and Otto C Boerman, and Patrick Meijer, and Wim J G Oyen, and Cees Tack, and Gerard A Rongen, and Paul Smits
November 2018, International journal of cardiology,
Richard Engbersen, and Niels P Riksen, and Marc J Mol, and Bert Bravenboer, and Otto C Boerman, and Patrick Meijer, and Wim J G Oyen, and Cees Tack, and Gerard A Rongen, and Paul Smits
September 2018, International journal of cardiology,
Richard Engbersen, and Niels P Riksen, and Marc J Mol, and Bert Bravenboer, and Otto C Boerman, and Patrick Meijer, and Wim J G Oyen, and Cees Tack, and Gerard A Rongen, and Paul Smits
April 2008, Current opinion in organ transplantation,
Copied contents to your clipboard!